The effects of the combined administration of β‐adrenoceptor antagonists and non‐steroidal anti‐inflammatory drugs on ligation‐induced arrhythmias in rats

Fagbemi, O.

doi:10.1111/j.1476-5381.1985.tb08869.x

Cited by 8 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, some NSAIDs have been shown to reduce the risk of ventricular arrhythmias in experimental models of ischaemia. The NSAIDs used in those studies included indomethacin, ketoprofen and mefenamic acid [76–79]. Studies on ibuprofen, conducted in both animals and humans, have shown conflicting results [80, 81].…”

Section: Discussionmentioning

confidence: 99%

Use of non‐steroidal anti‐inflammatory drugs and risk of incident myocardial infarction and heart failure, and all‐cause mortality in the Australian veteran community

Mangoni¹,

Woodman

Gaganis³

et al. 2010

Brit J Clinical Pharma

View full text Add to dashboard Cite

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Current evidence suggests the use of non‐steroidal anti‐inflammatory drugs (NSAIDs) increases the risk of myocardial infarction and heart failure. However, some studies have failed to demonstrate a significant relationship. • Differences in patient demographics, study design, and the varying types and classes of NSAIDs studied might either confound or modify the association between NSAID use and risk of myocardial infarction and heart failure, and prevent accurate data interpretation. WHAT THIS STUDY ADDS • NSAID use is not associated with an increased risk of either incident myocardial infarction or heart failure in elderly patients. • NSAID use is associated with a reduction in all‐cause mortality in this cohort. AIMS We studied the association between either non‐selective NSAIDs (ns‐NSAIDs), selective COX‐2 inhibitors, or any NSAID and risk of incident myocardial infarction (MI) and heart failure (HF), and all‐cause mortality in elderly subjects. METHODS We conducted a retrospective nested case‐control study on Australian veterans using nationwide hospital admission and pharmacy dispensing data. We estimated adjusted odds ratios (OR) with 95% confidence intervals (CI) for the risk of events for three different measures of prescription supply exposure over the last 2 years: (i) supplied at least once, (ii) supply frequency: supplied more than twice within the last 30 days, once or twice within the last 30 days, and once or more 30 days to 2 years and (iii) total supplies. RESULTS We identified 83 623 cases and 1 662 099 matched controls (1:20) contributing 3 862 931 persons‐years of observation. NSAID use at least once within the last 2 years did not significantly affect the risk of MI (OR 1.00, 95% CI 0.96, 1.04) but was associated with a mildly reduced risk of HF (OR 0.95, 95% CI 0.92, 0.98). There was a reduced all‐cause mortality with at least one supply of either ns‐NSAIDs (OR 0.94, 95% CI 0.90, 0.97), selective COX‐2 inhibitors (OR 0.90, 95% CI 0.88, 0.93), or any NSAID (OR 0.87, 95% CI 0.85, 0.90). Risk of death was also inversely associated with the number of prescription supplies. CONCLUSIONS NSAID use is not associated with an increased risk of incident MI and HF but is associated with a reduction in all‐cause mortality in Australian veterans.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of non‐steroidal anti‐inflammatory drugs and risk of incident myocardial infarction and heart failure, and all‐cause mortality in the Australian veteran community

Mangoni¹,

Woodman

Gaganis³

et al. 2010

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Recently, we have identified meclofenamate as a potent TRPM4 inhibitor using a thallium‐based screening (Vandewiele et al., 2022). Remarkably, previous research has reported that intravenous administration of 3 mg/kg meclofenamate can reduce ventricular arrhythmias induced by coronary artery ligation in anaesthetised rats (Fagbemi, 1984, 1985).…”

Section: Introductionmentioning

confidence: 94%

Exploring the role of TRPM4 in calcium‐dependent triggered activity and cardiac arrhythmias

Pironet

Vandewiele

Vennekens

2023

The Journal of Physiology

View full text Add to dashboard Cite

Cardiac arrhythmias pose a major threat to a patient's health, yet prove to be often difficult to predict, prevent and treat. A key mechanism in the occurrence of arrhythmias is disturbed Ca2+ homeostasis in cardiac muscle cells. As a Ca2+‐activated non‐selective cation channel, TRPM4 has been linked to Ca2+‐induced arrhythmias, potentially contributing to translating an increase in intracellular Ca2+ concentration into membrane depolarisation and an increase in cellular excitability. Indeed, evidence from genetically modified mice, analysis of mutations in human patients and the identification of a TRPM4 blocking compound that can be applied in vivo further underscore this hypothesis. Here, we provide an overview of these data in the context of our current understanding of Ca2+‐dependent arrhythmias. image

show abstract

“…Pharmacologically, the effect of blocking or activating the different adrenergic receptors in rats is ambiguous. Although β-adrenergic stimulation by isoprenaline is proarrhythmic, 53 blocking the β-adrenergic receptors have yielded both positive 35,104 -106 and negative results. 26,107 -109 Some investigators believe that the antiarrhythmic effect of β-blocking agents sometimes observed in rats is due to blockage of cardiac-β adrenergic receptors, 105 and others have suggested that the antiarrhythmic properties are due to peripheral effects, for example, increasing levels of serum K + 110 or neurokinin activity.…”

Section: Interventions Applied To Rat Models Of Vf Caused By Amimentioning

confidence: 99%

Rat Models of Ventricular Fibrillation Following Acute Myocardial Infarction

Hundahl

Tfelt-Hansen

Jespersen

2017

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

A number of animal models have been designed in order to unravel the underlying mechanisms of acute ischemia-induced arrhythmias and to test compounds and interventions for antiarrhythmic therapy. This is important as acute myocardial infarction (AMI) continues to be the major cause of sudden cardiac death, and we are yet to discover safe and effective treatments of the lethal arrhythmias occurring in the acute setting. Animal models therefore continue to be relevant for our understanding and treatment of acute ischemic arrhythmias. This review discusses the applicability of the rat as a model for ventricular arrhythmias occurring during the acute phase of AMI. It provides a description of models developed, advantages and disadvantages of rats, as well as an overview of the most important interventions investigated and the relevance for human pathophysiology.

show abstract

The effects of the combined administration of β‐adrenoceptor antagonists and non‐steroidal anti‐inflammatory drugs on ligation‐induced arrhythmias in rats

Cited by 8 publications

References 23 publications

Use of non‐steroidal anti‐inflammatory drugs and risk of incident myocardial infarction and heart failure, and all‐cause mortality in the Australian veteran community

Use of non‐steroidal anti‐inflammatory drugs and risk of incident myocardial infarction and heart failure, and all‐cause mortality in the Australian veteran community

Exploring the role of TRPM4 in calcium‐dependent triggered activity and cardiac arrhythmias

Rat Models of Ventricular Fibrillation Following Acute Myocardial Infarction

Contact Info

Product

Resources

About